BY MIKKEL AABENHUS HEMMINGSEN
-
Lundbeck writes down drug candidate by USD 79 million
A stage 1 test has actually disappointed the wanted outcomes.
-
Novo Holdings leads Series B round in cell therapy company
The firm was started in 2021 by Blackstone Life Sciences, Cellex Cell Professionals and Intellia Rehabs.
-
Europe continues to lose ground in clinical trials
The European share is now simply 9%, in comparison with 19% ten years in the past.
-
CHMP recommends ten new medicines
The company likewise suggests added applications for one more 6 medications.
-
FDA grants Breakthrough Therapy Designation to Boehringer Ingelheim’s survodutide
Boehringer Ingelheim has actually likewise introduced 2 stage III tests for survodutide to additionally explore the medication’s performance.
-
Fish skin from Coloplast acquisition effective as diabetic foot ulcer treatment
Diabetic foot abscess can be tough to deal with and can result in infection and also amputation otherwise appropriately dealt with.
-
Novo Nordisk to invest USD 158 million in Brazilian insulin plant
The news was made throughout a browse through to Brazil of Denmark’s Queen Mary.
-
Lilly shells out USD 4.5 billion for new drug development plant
Considering That 2020, Lilly has actually spent greater than USD 23 billion right into brand-new and existing plants.
-
Roche aims to deliver 20 new drugs in research overhaul
The firm is looking for to test Novo Nordisk and Eli Lilly in the expanding market for excessive weight therapies.
-
Novo Nordisk’s Wegovy-fueled gains fading as analyst doubts grow
JPMorgan’s Richard Vosser claimed in a note that the Danish business’s third-quarter record “can trigger some dissatisfaction.”
